Pharmaceuticals, Biotechnology and Life Sciences
Proceeds Will Fund Start-Up Activities for Current and Future Clinical Trials HIGH POINT, N.C.–(BUSINESS WIRE)–vTv Therapeutics Inc. (Nasdaq:VTVT) (the “Company”)…
LEXINGTON, Mass.–(BUSINESS WIRE)–Fractyl Laboratories Inc. (Fractyl) today announced the hiring of Margaret Borys as Chief Commercial Officer (CCO) and Juan…
Neratinib becomes the first anti-HER2 treatment to be approved in Australia, as extended adjuvant therapy for early stage HER2-positive breast…
— If Approved, AR101 Will Be the First Medicine for This Life-Threatening Condition — BRISBANE, Calif.–(BUSINESS WIRE)–Aimmune Therapeutics, Inc. (Nasdaq:…
FLEXBUMIN 25% [Albumin (Human)], USP, 25% Solution is indicated for hypovolemia, hypoalbuminemia, (burns, Adult Respiratory Distress Syndrome (ARDS), and nephrosis),…
ATHENS, Ga–(BUSINESS WIRE)–ArunA Bio, a leader in the development of exosomes and exosome therapeutics for the treatment of neurodegenerative disorders,…
OSAKA, Japan & MOUNTAIN VIEW, Calif.–(BUSINESS WIRE)–lt;a href="https://twitter.com/hashtag/ai?src=hash" target="_blank"gt;#ailt;/agt;–Ono Pharmaceutical Co., Ltd., a Japanese pharmaceutical research and development company, and…
CAMBRIDGE, England & BOSTON–(BUSINESS WIRE)–Bicycle Therapeutics, a biotechnology company pioneering a new class of therapeutics based on its proprietary bicyclic…
Respiratory Syncytial Virus (RSV) Human Challenge Study with EDP-938 ARGON-1 Study in Non-alcoholic Steatohepatitis (NASH) with EDP-305 WATERTOWN, Mass.–(BUSINESS WIRE)–lt;a…
First Subjects Dosed in Phase I Clinical Trial for Lead Autoimmune/Inflammatory Disease Program, ALPN-101 Completed $25 Million Private Placement Strong…